Tagged with Denmark

Denmark Maja Kramp, General Manager at Ferring Nordics, discusses the company’s long-standing commitment to innovation in reproductive medicine and the pivotal role of the Nordic region in Ferring’s global strategy. She highlights the region’s strong life sciences ecosystem, Denmark’s leadership in global R&D, and the company’s values of collaboration, care, and…

Denmark As Denmark’s life science sector matures into a globally engaged, innovation-led ecosystem, the Danish Life Science Cluster has emerged as a central neutral coordinating force, aligning regional strengths, shaping strategic direction, and enabling collaborative transformation across sectors. In this interview, Director Diana Arsovic Nielsen, CEO of the Cluster, reflects on…

Denmark Having become Europe’s number one pharma success story thanks largely to its blockbuster weight-loss drug, Wegovy, Novo Nordisk has been hit with stiff competition from Lilly and seen a steep decline in market performance. The Danish drugmaker has moved to oust its longstanding CEO and is looking to regain lost…

Denmark Ida Sofie Jensen, CEO of Lif, Denmark’s pharmaceutical industry association, discusses the country’s bold Life Science Strategy and the ongoing healthcare reform shaping its future. She explores how Denmark is aligning innovation, access, and health system sustainability through coordinated policymaking, a new Healthcare Innovation Index, and strengthened partnerships between industry…

Denmark With a mandate spanning pharmaceuticals, medical devices, and clinical research, the Danish Medicines Agency plays a central role in shaping both national health policy and European regulatory alignment. Under the leadership of Nils Falk Bjerregaard, the agency is navigating a period of accelerated transformation, defined by digitalisation, real-world evidence, decentralised…

Investment In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent – they’re fighting for the soul, and pockets, of the industry’s future. We spoke to the CEOs of regional investment…

Denmark Flemming Sonne, CEO of Amgros, Denmark’s central pharmaceutical procurement organization for hospital medicines, outlines the organisation’s evolving role in ensuring affordable and sustainable access to medicines. In this interview, Sonne discusses Denmark’s forward-thinking approach to supply chain resilience, the integration of ATMPs and innovative access models, and the increasing convergence…

Denmark Anette Steenberg, CEO of Medicon Valley Alliance, discusses how the Danish-Swedish cross-border innovation hub is positioning the region as a global leader in life sciences. The Alliance leverages regional strengths and a “triple helix” model of collaboration between hospitals, private companies, and academia in order to deliver world-class competitive value.…

Denmark Home to a score of pioneering biopharma players, Denmark has recognized its life sciences industry as a cornerstone of the economy. After forming a public-private partnership forum in 2021, the Danish Life Sciences Council (DLSC), the government laid out an ambitious strategy for the sector. The DLSC has now taken…

Denmark Zealand Pharma’s transformational journey from a niche biotech to a commercial-stage player in the booming global obesity market has reached another major milestone. As part of a USD 5.3 billion partnership with pharma giant Roche, Zealand will receive a USD 1.65 billion upfront payment, with Roche set to deliver Zealand’s…

Denmark A seasoned neuroscience researcher with firsthand experience of both successes and failures in one of biomedicine’s most challenging fields, Johan Luthman is better placed than most to comment on the past, present, and future of Alzheimer’s disease. Luthman, who currently serves as EVP and Head of R&D at Danish neuroscience…

Denmark As tensions rise over US-EU trade, will the weight-loss drug Ozempic become an unexpected bargaining chip? Stan Jackson explores the risks of leveraging GLP-1s in economic negotiations.   You can always tell when a blockbuster drug has entered the cultural zeitgeist. It’s around the time you start to hear the…